Oakland, CA, United States of America

Phillippe Bergeron

This inventor holds 1 USPTO granted patent. Top assignee: Genentech, Inc.. Active years: 2013.


Average Co-Inventor Count = 18.0

ph-index = 1

Forward Citations = 25(Granted Patents)


Company Filing History:


Years Active: 2013

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Phillippe Bergeron

Introduction

Phillippe Bergeron is an accomplished inventor based in Oakland, CA. He has made significant contributions to the field of pharmaceuticals, particularly in the development of novel compounds for medical use. His work focuses on addressing immunological and hyperproliferative disorders through innovative chemical compositions.

Latest Patents

Phillippe holds a patent for "Tricyclic heterocyclic compounds, compositions and methods of use thereof." This invention provides novel compounds of formula I, which are designed to be used in pharmaceutically acceptable compositions. These compounds are intended for the treatment of various medical conditions, showcasing his commitment to advancing healthcare solutions.

Career Highlights

Phillippe is currently employed at Genentech, Inc., a leading biotechnology company known for its focus on innovative medicines. His role at Genentech allows him to collaborate with other talented professionals in the field, further enhancing his contributions to pharmaceutical research and development.

Collaborations

Some of his notable coworkers include Srinivasan Babu and Hazel Joan Dyke. Their collaboration fosters a dynamic environment for innovation and discovery, enabling the team to push the boundaries of what is possible in medical science.

Conclusion

Phillippe Bergeron's work exemplifies the spirit of innovation in the pharmaceutical industry. His patent and contributions to Genentech, Inc. highlight his dedication to improving health outcomes through scientific advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…